Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.